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Abstract
From 1 January to 31 December 2011, 29 institu-
tions around Australia participated in the Australian 
Enterococcal Sepsis Outcome Programme 
(AESOP). The aim of AESOP 2011 was to deter-
mine the proportion of enterococcal bacteraemia 
isolates in Australia that are antimicrobial resistant, 
with particular emphasis on susceptibility to ampi-
cillin and the glycopeptides, and to characterise the 
molecular epidemiology of the Enterococcus fae-
calis and E. faecium isolates. Of the 1,079 unique 
episodes of bacteraemia investigated, 95.8% were 
caused by either E. faecalis (61.0%) or E. faecium 
(34.8%). Ampicillin resistance was detected in 
90.4% of E. faecium but not detected in E. faecalis. 
Using Clinical and Laboratory Standards Institute 
breakpoints (CLSI), vancomycin non-susceptibility 
was reported in 0.6% and 31.4% of E. faecalis 
and E. faecium respectively and was predomi-
nately due to the acquisition of the vanB operon. 
Approximately 1 in 6 vanB E. faecium isolates 
however, had an minimum inhibitory concentra-
tion at or below the CLSI vancomycin susceptible 
breakpoint of ≤ 4 mg/L. Overall, 37% of E. fae-
cium harboured vanA or vanB genes. Although 
molecular typing identified 126 E. faecalis pulsed-
field gel electrophoresis (PFGE) pulsotypes, more 
than 50% belonged to 2 pulsotypes that were 
isolated across Australia. E. faecium consisted of 
73 PFGE pulsotypes from which 43 multilocus 
sequence types were identified. Almost 90% of the 
E. faecium were identified as clonal complex 17 
clones, of which approximately half were charac-
terised as sequence type 203, which was isolated 
Australia-wide. In conclusion, the AESOP 2011 
has shown that although polyclonal, enterococcal 
bacteraemias in Australia are frequently caused by 
ampicillin-resistant vanB E. faecium. Commun Dis 
Intell 2014;38(3):E247–E252.
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Introduction
Globally, enterococci are thought to account for 
approximately 10% of all bacteraemias,1 and in 
North America and Europe are the 4th and 5th 
leading cause of sepsis, respectively.2 Although 
in the 1970s, healthcare-associated enterococcal 
infections were primarily due to Enterococcus 
faecalis,3 there has been a steadily increasing preva-
lence of E. faecium nosocomial infections.4,5 While 
innately resistant to many classes of antibiotics, 
E. faecium has demonstrated a remarkable capac-
ity to evolve new antimicrobial resistances. By the 
early 1990s vancomycin resistant E. faecium had 
become the 2nd most common nosocomial patho-
gen in the United States of America (USA),6 and 
was endemic in many North American hospitals.7 
Vancomycin resistance in E. faecium bacteraemia 
isolates ranges from 5%–35% in Europe to 60% in 
North America.8,9 In 2009, the Infectious Diseases 
Society of America highlighted E. faecium as 
one of the key problem bacteria or ESKAPE 
(Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumanii, 
Pseudomonas aeruginosa, and Enterobacter species) 
pathogens requiring new therapies.10
The Australian Group on Antimicrobial Resistance 
(AGAR) is a network of laboratories located across 
Australia that commenced surveillance of anti-
microbial resistance in Enterococcus species in 
1995.11 In 2011, AGAR commenced the Australian 
Enterococcal Sepsis Outcome Programme 
(AESOP). The objective of the AESOP 2011 was to 
determine the proportion of E. faecalis and E. fae-
cium bacteraemia isolates demonstrating antimicro-
bial resistance with particular emphasis on:
• assessing susceptibility to ampicillin;
• assessing susceptibility to glycopeptides; and
• molecular epidemiology of E. faecalis and 
E. faecium.
Methodology
Participants
Twenty-nine laboratories including 26 public and 
3 private laboratories from all 8 Australian states and 
territories participated in the AESOP 2011 study.
Collection period
From 1 January to 31 December 2011, 29 laborato-
ries collected all enterococcal species isolated from 
blood cultures. Enterococci with the same species 
and antimicrobial susceptibility profiles isolated 
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from a patient’s blood culture within 14 days of 
the 1st positive culture were excluded. A new 
enterococcal sepsis episode in the same patient was 
recorded if it was confirmed by a further culture 
of blood taken more than 14 days after the initial 
positive culture.
Laboratory testing
Ampicillin susceptibility testing was performed 
according to each laboratory’s routine stand-
ardised methodology. Clinical and Laboratory 
Standards Institute (CLSI) breakpoints were uti-
lised for interpretation.12 Of the 1,033 E. faecalis 
and E. faecium sepsis isolates, 963 (93.2%) were 
referred to the Australian Collaborating Centre 
for Enterococcus and Staphylococcus Species 
(ACCESS) Typing and Research for vancomycin 
and teicoplanin minimum inhibitory concentra-
tion (MIC) estimation by Etest (bioMérieux) 
according to the manufacturer’s guidelines. 
Isolates with a CLSI intermediate or resistant 
category were classified as non-susceptible. 
Molecular testing including vanA/B polymerase 
chain reaction, pulsed-field gel electrophoresis 
(PFGE) and multilocus sequence typing (MLST) 
was performed as previously described.13–15
Results
From 1 January to 31 December 2011, 1,079 unique 
episodes of enterococcal bacteraemia were identi-
fied. Although 8 Enterococcus species were identi-
fied, 61.0% (658 isolates) were E. faecalis and 34.8% 
(375) were E. faecium. Forty-five enterococci were 
identified either as E. casseliflavus (15 isolates), 
E. gallinarum (14), E. avium (8), E. raffinosus (4), 
E. durans (2) or E. hirae (2). One isolate could not 
be identified to the species level.
Phenotypic susceptibility results
Overall 90.4% (339) of the 375 isolates of E. 
faecium were ampicillin resistant. Ampicillin 
resistance was not detected in the 658 E. faecalis 
isolates. Vancomycin and teicoplanin MICs were 
performed on the 622 E. faecalis and 341 E. fae-
cium referred to ACCESS Typing and Research. 
The vancomycin MICs for the E. faecalis isolates 
ranged from 0.25–>256 mg/L with a mode of 
2 mg/L. The 3 vancomycin non-susceptible 
isolates (MIC >4 mg/L) had MICs of 16, 32 
and >256 mg/L, respectively. The E. faecalis 
teicoplanin MICs ranged from 0.064–2 mg/L 
with a mode of 0.25 mg/L. None of the E. faecalis 
isolates had a teicoplanin MIC above the CLSI 
susceptible breakpoint of ≤8 mg/L. The vanco-
mycin MICs for the E. faecium isolates ranged 
from 0.25–>256 mg/L with a mode of 1.0 mg/L. 
Overall, 31.4% (107 isolates) of E. faecium had a 
vancomycin MIC >4 mg/L. The E. faecium teico-
planin MICs ranged from 0.047–>256 mg/L, 
with a mode of 0.5 mg/L. Five isolates had a 
teicoplanin MIC >8 mg/L.
Genotypic vancomycin susceptibility results
The 3 vancomycin non-susceptible E. faecalis 
isolates harboured a vanB gene. Two and 104 of 
the 107 E. faecium vancomycin non-susceptible 
isolates harboured vanA and vanB genes respec-
tively. The vanA/vanB negative vancomycin 
non-susceptible E. faecium isolate had a MIC of 
6 mg/L. Twenty of the 234 vancomycin suscep-
tible E. faecium isolates (MIC ≤4 mg/L) also 
harboured vanB genes. The 2 vanA E. faecium 
isolates had a vancomycin MIC >256 mg/L. 
Thirty-three vancomycin non-susceptible E. fae-
cium isolates had a vancomycin MIC within the 
CLSI intermediate category of 8–16 mg/L. Only 
71 (57.2%) of the 124 vanB E. faecium isolates 
had a MIC above the CLSI vancomycin resistant 
breakpoint (≥32 mg/L). The 2 vanA E. faecium 
isolates had teicoplanin MICs of 32 and 64 mg/L. 
Of the 124 vanB E. faecium isolates one was teico-
planin intermediate (MIC 16 mg/L) and three 
were resistant (MIC >32 mg/L) by CLSI criteria.
Molecular epidemiology
By PFGE, 618 of the 622 E. faecalis were classified 
into 126 pulsotypes of which 9 pulsotypes (Efs1 to 
Efs9) had 10 or more isolates. Four isolates could not 
be typed by PFGE. Of the 117 pulsotypes that have 
less than 10 isolates, 66 pulsotypes were represented 
by only 1 isolate. Geographically, the 9 major pulso-
types were widely distributed, with the 2 predominant 
pulsotypes EFs1 (191 isolates) and Efs2 (103 isolates), 
isolated across Australia (Table 1). The 3 vanB E. fae-
calis were detected in pulsotype Efs2.
By PFGE, the 341 E. faecium isolates were classi-
fied into 73 pulsotypes from which 43 multilocus 
sequence types (STs) were identified. Five STs had 
more than 10 isolates (Table 2). The 2 major STs, 
ST203 (159 isolates) and ST17 (47 isolates) were 
isolated across Australia. ST341 (38 isolates) and 
ST252 (11 isolates) were isolated only in the eastern 
regions of Australia, and ST555 (34 isolates) was 
isolated in the western and central regions. Using 
eBURST, 89.1% (304/341 isolates) of E. faecium iso-
lates, including the 5 major STs, were grouped into 
clonal complex (CC) 17. Van genes were identified in 
the 5 major STs and in ST80 and ST414. Although 
only 8.5% (4/47) of ST17 isolates harboured vanB, 
vanB genes were identified in 50.6% (79/153) of 
ST203 isolates. Other STs harbouring the vanB 
genes included ST341 (33/38), ST555 (2/34), ST252 
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(1/11), ST80 (2/6), ST414 (2/2), and a single non-
CC17 isolate, ST863. Two CC17 STs harboured the 
vanA gene; ST341 and ST80.
Discussion
AESOP 2011 was the 1st ongoing sepsis program 
performed by AGAR, and was conducted primar-
ily to determine the proportion of E. faecalis and 
E. faecium bacteraemia isolates demonstrating 
antimicrobial resistance, with particular emphasis 
on assessing susceptibility to penicillin and the 
glycopeptides and the distribution of different 
enterococcal clones. As this is the 1st year of an 
ongoing program, it is difficult to determine the 
public health significance of these results. We sug-
gest these results should be used as a marker for 
future AESOPs.
Similar to the situation in the USA and in 
Europe,16,17 enterococcal bacteraemia in Australia, 
and notably bacteraemia caused by multidrug-
resistant E. faecium, has become a significant 
problem. In the AESOP 2011 study, approximately 
1 in 3 cases of enterococcal bacteraemia was due 
to E. faecium, of which 90.4% (339 of 375 epi-
sodes) were ampicillin resistant and 36.9% (126 
of 341 episodes) harboured either vanA or vanB 
genes. However, unlike Europe and the USA, 
where vancomycin resistance in E. faecium has 
predominately been due to the acquisition of the 
vanA operon, almost all of the AESOP 2011 E. fae-
cium blood culture isolates harbouring van genes 
carried the vanB operon (98.4%). Recent studies 
however, have demonstrated a significant presence 
of vanB E. faecium in both North America and 
Europe.18–20
vanB vancomycin resistant enterococci (VRE) is 
now more prevalent than vanA VRE in several 
European centres including Sweden, Spain and 
Germany,21–23 whilst recent Canadian national 
surveillance demonstrates vanB comprises 10% 
of their VRE.24 It is thought this increased occur-
rence of vanB-positive E. faecium in the Northern 
Hemisphere may be due to the increased use of 
antibiotics selecting enterococci and VRE as well as 
to methodological reasons (e.g. reduced European 
Committee on Antimicrobial Susceptibility 
Testing (EUCAST) MIC breakpoints for glyco-
peptides; increased use and sensitive performance 
of chromogenic VRE agars; increased use of 
molecular diagnostic assays).25 Twenty (16.1%) of 
the 124 vanB E. faecium isolates had a vancomy-
cin MIC at or below the CLSI and the EUCAST 
susceptible breakpoint (≤4 mg/L) and would not 
have been identified using routine phenotypic 
antimicrobial susceptibility methods.
With the use of PFGE, both enterococcal species 
were shown to be very polyclonal, confirming the 
enormous plasticity of the enterococcal genome. 
The majority of E. faecium isolates formed part 
of CC17, a global hospital-derived lineage that 
has successfully adapted to hospital environ-
ments. CC17 is characteristically ampicillin and 
quinolone resistant and subsequent acquisition of 
vanA– or vanB-containing transposons by hori-
zontal transfer in CC17 clones has resulted in VRE 
with pandemic potential.
The study has a number of limitations. Although 
achieving national coverage, the participating lab-
oratories service only a minority of the Australian 
hospitalised population. Further, MIC assays for 
vancomycin and teicoplanin were performed by a 
commercial gradient diffusion method and not the 
standard reference broth microdilution method.
Conclusions
The AESOP 2011 study has shown though pre-
dominately caused by E. faecalis, enterococcal 
bacteraemia in Australia is frequently caused by 
ampicillin-resistant vanB E. faecium. Molecular 
typing characterised over 50% of E. faecalis 
isolates as 2 PFGE pulsotypes and almost 90% 
of E. faecium isolates as CC17 clones of which 
approximately half were ST203. Further studies 
of the enterococcal genome will contribute to our 
understanding of the evolution of enterococci in 
the hospital environment and assist in preventing 
their nosocomial transmission.
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